基于酸盐的混合多糖体气凝 药物输送微粒:制备,表征和性能评估
Mohammad Alnaief1, Balsam Mohammad1, Ibrahem Altarawneh1
1Pharmaceutical and Chemical Engineering Department, School of Applied Medical Sciences, German Jordanian University, Amman Madaba Street, P.O. Box 35247, Amman 11180, Jordan.
Gels (Basel, Switzerland)
|October 28, 2025
概括
混合多糖体气凝显示出快速药物输送的承诺. 一种阿尔金酸盐/卡拉基南混合气凝显示出高布洛芬加载和快速释放,与商业产品相匹配.
科学领域:
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
- 药物输送系统 药物输送系统
背景情况:
- 基于多糖的气凝由于其结构,多孔性和生物相容性,有望用于药物输送.
- 与单个聚合物相比,混合配方可以增强气凝的性能.
研究的目的:
- 为了合成和表征混合型多糖体气凝微粒用于药物输送.
- 评估这些新型气凝的药物加载和释放动力学.
主要方法:
- 通过乳液凝和超临界CO2提取,使用酸盐,点,卡拉基合成的空气凝微粒.
- 描述包括SEM,气体吸附,XRD,TGA,DSC和FTIR.
- 使用混合阿尔金酸盐/卡拉基南配方评估的布洛芬加载和释放动力学.
主要成果:
- 混合气凝呈现出具有高表面积 (324-521 m2/g) 和孔积 (1.99-3.75 cm3/g) 的中孔结构.
- 杂交改善了形态统一性和热稳定性.
- 酸/卡拉基南 (2:1) 混合体显示了93.5%的药物加载效率和快速的布洛芬释放 (>90%在15分钟内).
- 药物释放跟随了Fickian扩散动力学.
结论:
- 混合多糖体气凝,特别是酸盐/卡拉基南,是有效的药物输送平台.
- 这些气凝为快速起作用的治疗应用提供了可调节的特性.
- 开发的气凝显示出与商业药物配方相美的潜力.
相关概念视频
Pore Transport and Ion-Pair Transport
Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


